Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

Zacks03-28

Lantheus Holdings, Inc. LNTH has been gaining from its focus on pipeline development. The optimism led by a solid fourth-quarter 2023 performance and strength in radiopharmaceuticals is expected to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422119748?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61","is_english":true,"pubTime":"2024-03-28 22:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2422119748","market":"us","top_or_hot":-1,"title":"Here's Why You Should Add Lantheus (LNTH) to Your Portfolio","media":"Zacks","content":"<div>\n<p>Lantheus Holdings, Inc. LNTH has been gaining from its focus on pipeline development. The optimism led by a solid fourth-quarter 2023 performance and strength in radiopharmaceuticals is expected to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-add-lantheus-lnth-140400366.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Add Lantheus (LNTH) to Your Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Add Lantheus (LNTH) to Your Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-28 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-add-lantheus-lnth-140400366.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lantheus Holdings, Inc. LNTH has been gaining from its focus on pipeline development. The optimism led by a solid fourth-quarter 2023 performance and strength in radiopharmaceuticals is expected to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-add-lantheus-lnth-140400366.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0114720955.EUR","symbol_name":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-add-lantheus-lnth-140400366.html","article_id":"2422119748","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422119748","pubTimestamp":1711634640,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Over the past year, the Zacks Rank #1  stock has lost 2.5% against the 5.5% rally of the industry. The S&P 500 has witnessed 9.9% growth in the said time frame.Based on estimates from third-party sources regarding the incidence of prostate cancer in men in the United States, Lantheus believes the market potential for PSMA PET imaging agents in the country could be up to 350,000 annual scans, comprising 125,000 scans for patients with an intermediate, unfavorable or high or very high risk of suspected metastases of prostate cancer and 195,000 scans for patients with suspected recurrence of prostate cancer, among others. Earlier this month, the FDA approved label expansion for DEFINITY  as an ultrasound-enhancing agent for use in pediatric patients with suboptimal echocardiograms.Macroeconomic Concerns: Lantheus’ operational and financial success are significantly influenced by various factors, many of which are outside its control. The current economic environment and financial market c","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","SYK":"史赛克","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","PET":"Wag! Group Co","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4175":"保健护理产品经销商","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4192":"特殊消费者服务","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","LNTH":"Lantheus Holdings, Inc.","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4566":"资本集团","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4196":"保健护理服务","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","DVA":"达维塔保健","BK4082":"医疗保健设备","BK4559":"巴菲特持仓","LU0882574055.USD":"富达全球健康医疗A ACC","BK4588":"碎股","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","BK4198":"医疗保健用品","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","CAH":"卡地纳健康","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4504":"桥水持仓"},"translate_title":"以下是你应该将Lantheus（第n名）加入投资组合的原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1,"LNTH":1,"DVA":1,"CAH":1,"PET":1},"content_text":"Lantheus Holdings, Inc. LNTH has been gaining from its focus on pipeline development. The optimism led by a solid fourth-quarter 2023 performance and strength in radiopharmaceuticals is expected to contribute further. However, dependence upon third parties and macroeconomic concerns are major downsides.\nOver the past year, the Zacks Rank #1 (Strong Buy) stock has lost 2.5% against the 5.5% rally of the industry. The S&P 500 has witnessed 9.9% growth in the said time frame.\nThe renowned radiopharmaceutical-focused player has a market capitalization of $4.03 billion. The company projects 5.6% growth for 2024 and expects to witness continued improvements in its business. Lantheus’ earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average earnings surprise being 14.8%.\nImage Source: Zacks Investment Research\nLet’s delve deeper.\nPipeline Development: We are optimistic about Lantheus actively developing its pipeline with promising assets like PNT2002 and PNT2003. In December 2022, the company announced the closing of a set of collaborations with POINT Biopharma Global Inc. (“POINT”). This granted Lantheus exclusive worldwide rights (excluding Japan, South Korea, China including Hong Kong, Macau and Taiwan; Singapore and Indonesia) to co-develop and commercialize POINT’s PNT2002 and PNT2003 product candidates.\nStrength in Radiopharmaceuticals: Lantheus has established itself as a leader in the radiopharmaceutical sector, particularly in prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging, where its product, PYLARIFY, has a strong demand.\nBased on estimates from third-party sources regarding the incidence of prostate cancer in men in the United States, Lantheus believes the market potential for PSMA PET imaging agents in the country could be up to 350,000 annual scans, comprising 125,000 scans for patients with an intermediate, unfavorable or high or very high risk of suspected metastases of prostate cancer and 195,000 scans for patients with suspected recurrence of prostate cancer, among others. Earlier this month, the FDA approved label expansion for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound-enhancing agent for use in pediatric patients with suboptimal echocardiograms.\nStrong Q4 Results: Lantheus’ fourth-quarter 2023  top-line and bottom-line performance was solid. Robust segmental results were also registered, with continued strength in PYLARIFY and DEFINITY. The expansion of gross margin was also seen.\nDownsides\nMacroeconomic Concerns: Lantheus’ operational and financial success are significantly influenced by various factors, many of which are outside its control. The current economic environment and financial market conditions present unpredictable challenges to the business. There is a risk of reduced demand for healthcare services and pharmaceuticals due to various factors, which could affect revenues. This, in turn, might result in delayed or canceled orders, hurting the company's financial stability and liquidity.\nDependence Upon Third Parties: PYLARIFY is produced by a network of PET manufacturing facilities (PMFs) across the nation, each requiring separate FDA approval. Despite ongoing efforts to qualify additional PMFs, there's uncertainty regarding the FDA's continued approvals and the PMFs' manufacturing capabilities, which could adversely impact Lantheus’ future operations and financial health.\nEstimate Trend\nLantheus has been witnessing a positive estimate revision trend for 2024. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has moved 5.1% north to $6.58.\nThe Zacks Consensus Estimate for first-quarter 2024 revenues is pegged at $349 million.\n\nLantheus Holdings, Inc. Price\n\nLantheus Holdings, Inc. price | Lantheus Holdings, Inc. Quote\n\nOther Stocks to Consider\nSome other top-ranked stocks in the broader medical space are Cardinal Health CAH, Stryker SYK and DaVita DVA. While Cardinal Health and Stryker each carry a Zacks Rank #2 (Buy), DaVita sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nCardinal Health’s stock has surged 50.9% in the past year. Earnings estimates for Cardinal Health have risen from $7.28 to $7.29 in fiscal 2024 and from $8.02 to $8.04 in fiscal 2025 in the past 30 days.\nCAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.67%.\nEstimates for Stryker’s 2024 earnings per share have remained constant at $11.86 in the past 30 days. Shares of the company have moved 28.5% upward in the past year compared with the industry’s rise of 5.2%.\nSYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.09%. In the last reported quarter, it delivered an average earnings surprise of 5.81%.\nEstimates for DaVita’s 2024 earnings per share have moved up from $8.97 to $9.23 in the past 30 days. Shares of the company have surged 74.4% in the past year compared with the industry’s 22% rise.\nDVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.57%. In the last reported quarter, it delivered an average earnings surprise of 22.22%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nStryker Corporation (SYK) : Free Stock Analysis Report\nDaVita Inc. (DVA) : Free Stock Analysis Report\nCardinal Health, Inc. (CAH) : Free Stock Analysis Report\nLantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422119748"}